Heidelberg Pharma disclosed in its July 15 half-year report that the Phase I dose-escalation portion of the HDP-101 study has been completed across ten cohorts and that the recommended Phase II dose has been…
The FDA approved subcutaneous Sarclisa (isatuximab-irfc) Escena across all existing Sarclisa IV indications in multiple myeloma. It is the first anticancer treatment administered via an on-body injector, and the first myeloma therapy available by…
Telo Genomics filed a U.S. provisional patent application to protect a new TeloView biomarker algorithm designed for use with liquid biopsy samples, including those at minimal residual disease levels, in the management of patients…
Kelonia Therapeutics presented updated ASCO 2026 data supporting continued advancement of its in vivo CAR-T platform, which engineers CAR-T cells directly inside patients using targeted lentiviral delivery technology.
CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development.
Tempest Therapeutics reported its year-end 2025 business update, highlighting two key developments: the acquisition of dual-targeting CAR-T assets from Factor Bioscience and positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003…
